Revelation Biosciences

REVB

Market cap $2.69M

Overview Fund Activity

1.58 USD

+0.02

1.28%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

1.64

+0.06

3.8%

1 day

1.28%

5 days

-41.7%

1 month

-41.7%

3 months

-34.44%

6 months

-82.44%

Year to date

-94.99%

1 year

-96.34%

5 years

-100%

10 years

-100%

About: Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Employees: 9

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

382% more capital invested

Capital invested by funds: $13.3K [Q1] → $64.2K (+$50.9K) [Q2]

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

17% more funds holding

Funds holding: 6 [Q1] → 7 (+1) [Q2]

2.63% more ownership

Funds ownership: 0.31% [Q1] → 2.94% (+2.63%) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 4 articles about REVB published over the past 30 days

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,355,000 shares of common stock, issued by the Company on May 29, 2025 (the "Existing Warrants"), at the existing exercise price of $2.20 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-1 (File No.

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - Data discussion webcast/conference call will be held at 8:30 am Eastern Time SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, will host a corporate update webcast/conference call (details below) at 8:30 am Eastern Time to review groundbreaking activity data from its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease (CKD) patients. The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met.

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th webcast at 8:30 am Eastern Time, which can be accessed here or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use the participant access code 289672. We look forward to reviewing the data with you tomorrow morning.

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - Data discussion webcast/conference call will be held on Wednesday, September 10th at 8:30 am Eastern Time SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced positive safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease (CKD) patients. The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met.

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team con.

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (Nasdaq: REVB) the “Company” or “Revelation”) a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today congratulates its former chairman and shareholder, George Tidmarsh, MD, PhD, who has been selected to head the FDA Center for Drug Evaluation and Research. “George was the chairman of the board of our company, Revelation Biosciences, Inc., as well as one of the founders,” said James Rolke, Pres.

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). As planned, a total of 5 cohorts were enrolled at 3 cl.

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existin.

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated.

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants w.

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

See News Rankings

Charts implemented using Lightweight Charts™